Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 132.27M P/E - EPS this Y -22.10% Ern Qtrly Grth -
Income -130.32M Forward P/E -0.91 EPS next Y 1.40% 50D Avg Chg 12.00%
Sales - PEG -0.02 EPS past 5Y - 200D Avg Chg -71.00%
Dividend N/A Price/Book 0.57 EPS next 5Y 38.60% 52W High Chg -86.00%
Recommedations 1.80 Quick Ratio 11.16 Shares Outstanding 38.56M 52W Low Chg 67.00%
Insider Own 2.92% ROA -25.41% Shares Float 26.60M Beta -
Inst Own 109.39% ROE -45.24% Shares Shorted/Prior 2.20M/2.32M Price 3.43
Gross Margin - Profit Margin - Avg. Volume 603,535 Target Price 29.25
Oper. Margin - Earnings Date May 16 Volume 247,183 Change 3.94%
Annexon, Inc. News
05/09/22 Annexon Biosciences Highlights Portfolio Progress and Key Anticipated Milestones, and Reports First Quarter 2022 Financial Results
05/05/22 Annexon Biosciences to Participate in Upcoming May Investor Conferences
04/21/22 Insider Buying: The Annexon, Inc. (NASDAQ:ANNX) CEO, President & Director Just Bought 59% More Shares
04/18/22 Is Annexon (NASDAQ:ANNX) In A Good Position To Invest In Growth?
04/07/22 Annexon Biosciences Completes Enrollment in ARCHER Phase 2 Trial of Novel C1q Inhibitor, ANX007, in Patients with Geographic Atrophy
04/04/22 Annexon Biosciences to Participate in the 21st Annual Needham Virtual Healthcare Conference
03/03/22 Annexon Biosciences to Present Preclinical Data Supporting Complement Inhibitor Programs for the Treatment of Guillain-Barré Syndrome and Huntington’s Disease at AAN 2022
03/01/22 Annexon Biosciences Announces Program Highlights and Reports Fourth Quarter and Full Year 2021 Financial Results
02/28/22 Annexon Biosciences to Participate in the Cowen 42nd Annual Healthcare Conference
01/20/22 Annexon Biosciences Appoints Bettina M. Cockroft, M.D. to its Board of Directors
01/05/22 Why Annexon Biosciences Stock Plummeted 34% Today
01/05/22 Annexon's Interim Mid-Stage Results On Huntington's Disease Candidate Fails To Cheer
01/04/22 Annexon Biosciences Reports Promising Interim Phase 2 Data Showing Improvement in Clinical Measures with ANX005 in Huntington’s Disease Following Six-Month Treatment
01/04/22 Annexon Biosciences to Present at the 40th Annual J.P. Morgan Healthcare Conference
12/31/21 Do Options Traders Know Something About Annexon (ANNX) Stock We Don't?
12/13/21 Annexon Biosciences Announces Clinical and Preclinical Data Highlighting Potential of Complement-Targeting Programs at the 63rd ASH Annual Meeting & Exposition
11/30/21 10 Pharmaceutical Stocks to Buy Under $20 According to Jeremy Green’s Redmile Group
11/28/21 3 “Strong Buy” Stocks for Bottom-Fishing Investors
11/09/21 Annexon Biosciences Announces Business and Program Highlights and Reports Third Quarter 2021 Financial Results

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.

ANNX Chatroom

User Image Alejos11 Posted - 1 hour ago

$ANNX 🏆🦍

User Image parab0licthe0ry Posted - 9 hours ago

$ANNX Improved the wyckoff scanner to focus on volume rather than price action and these two show impressive 'smart money' accumulation. Bottom is in imo. Both showing impressive volume support. Might park some money at break of monthly highs.

User Image InsiderForms Posted - 1 day ago

Fairmount Funds Management LLC,has filed Form 13F for Q1 2022.Opened NEW positions in $ANNX $OLMA $PTGX

User Image parab0licthe0ry Posted - 1 day ago

Wyckoff scanner showing these as "smart money accumulation" Not a recommendation to buy except for IMTE buy you never know $SLQT $SNAX $ANNX

User Image shortvolumes Posted - 2 days ago

Short sale volume (not short interest) for $ANNX at 2022-05-13 is 46%. http://shortvolumes.com/?t=ANNX via @shortvolumes

User Image bottlerocket2 Posted - 4 days ago

$ANNX in

User Image tickeron Posted - 5 days ago

This is why Hedge Funds use A.I. $ANNX's price moved below its 50-day Moving Average on May 11, 2022. View odds for this and other indicators: https://srnk.us/go/3657549

User Image shortablestocks Posted - 5 days ago

Zero shares available to short currently in $ANNX. https://www.shortablestocks.com/?ANNX

User Image EarningsInsider Posted - 5 days ago

Cantor Fitzgerald Raises Annexon FY2022 Earnings Estimates to ($3.86) EPS (Previously ($4.38)). https://www.marketbeat.com/x/1235547 $ANNX

User Image TheDoc7 Posted - 6 days ago

$ANNX Be careful. HC Wainwright’s gonna dump this on everybody’s heads. They always do. Instead of holding I actually sold this time. Good luck guys

User Image PLATINUM_TRADES Posted - 6 days ago

$ANNX $3.35 high for a good day🥦🥦🥦🥦

User Image PLATINUM_TRADES Posted - 6 days ago

$ANNX $3.30 to break our only overnight as I'm being careful.. Doing great🥦🥦🥦🥦

User Image Alejos11 Posted - 6 days ago

@Alejos11 Tomorrow’s watchlist 2 $ANNX $CARA $TRHC $RCKT $MYOV

User Image hmstocktwits Posted - 6 days ago

$ANNX Lower PT news, not sure but something to look at.

User Image Alejos11 Posted - 6 days ago

@Alejos11 alerts performance update $SKYH alrt is 🆙 28% $CYN 🆙 211% $ANNX 🆙 33% $JCSE 🆙 40%

User Image PLATINUM_TRADES Posted - 6 days ago

$ANNX keeping it for tomorrow I think we see a lot more especially premarket🥦🥦🥦🥦

User Image TradeAlertsTeam Posted - 6 days ago

🚨Relative Volume🚨%increase $BAOS $MICT $AKBA $ANNX $TCRX Stay tune for more ideas! You know where to find our team!

User Image The Rocking Horse Winner Posted - 6 days ago

$ANNX -- 3.20 May 10, 2022 not a big fan of biotechs at all so this is just a tentative buy paper-trade

User Image Alejos11 Posted - 1 week ago

$ANNX 💰🐎🐎

User Image Cranmer00 Posted - 1 week ago

Evolution Trading's Swings!! $FREQ $ANNX $BBLN YEEEEEEEEEEEEE HAW - Make sure to hedge with this garbage market .

User Image BlessedStockTrader3 Posted - 1 week ago

$ANNX wow looking good!!!! 👀

User Image Alejos11 Posted - 1 week ago

$ANNX Beautiful returns in a tough market 🏆🏆🏆

User Image tradesprofit Posted - 1 week ago

🔥HOT🔥 stocks today $BWV $CYN $ANNX $TCRX $VRM

User Image Trendrebel Posted - 1 week ago

$ANNX thanksful to this little diamond. Next to Jump $MEIP and probably $NILE when all the bagholders are washed

User Image algoslinger Posted - 1 week ago

$ANNX is up 10.385% from market open on 396,197 volume. Now trading at $2.87. #ANNX #tenpercentscan

User Image Stockboi_ Posted - 1 week ago

$ANNX sold too soon. I think this will pop harder off that price target news 🏃🏾‍♂️

User Image stocktargetadvisors Posted - 1 week ago

$ANNX latest rating from HC Wainwright on 2022-05-10, setting target price at: USD 30.00 with a rating of . StockTargetAdvisor's own view is Slightly Bearish with an average target price of USD 32.00. Details: https://www.stocktargetadvisor.com/stock/USA/NSD/ANNX

User Image Newsfilter Posted - 1 week ago

$ANNX HC Wainwright & Co. analyst Andrew Fein maintains Annexon with a Buy and lowers the price target from $40 to $30.

User Image MarketBeat Posted - 1 week ago

Annexon's PT cut by HC Wainwright to $30.00. https://www.marketbeat.com/r/1762030 $ANNX

User Image STCKPRO Posted - 1 week ago

$ANNX NEW ARTICLE : Annexon Biosciences (ANNX) Receives a Buy from Needham https://www.stck.pro/news/ANNX/27489745

Analyst Ratings
Needham Buy Apr 8, 22
HC Wainwright & Co. Buy Nov 30, 21
Cantor Fitzgerald Overweight Sep 23, 21
Needham Buy Jan 26, 21
B of A Securities Buy Aug 18, 20
Cowen & Co. Outperform Aug 18, 20
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Love Douglas President & CEO President & CEO Apr 14 Buy 2.4469 60,000 146,814 200,942 04/18/22